CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The DECOD-Ag project aims to enhance cancer immunotherapy by developing a high-throughput platform to identify immunogenic tumour neoantigens. This innovative technology will enable personalized treatment strategies, improving efficacy and reducing side effects in cancer patients.
Immunotherapy has revolutionised cancer treatment, providing survival benefits in patients with hard-to-treat tumours.
Tragically, these benefits are unevenly distributed.
Clinical efficacy varies dramatically between (and within) cancer types, and severe side-effects persist.
To address this, new treatment strategies seek the rational design of personalised therapies to achieve full eradication of most cancers.
Such a vision can be achieved by inducing immune responses against the ultimate tumo…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
TECHNICAL UNIVERSITY OF DENMARK DTU
Denmark, Kongens Lyngby
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, London
Type: Research institute
Activity type: Research Organisations
SME: No
Israel, Rehovot
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
ACHILLES THERAPEUTICS UK LIMITED
United Kingdom, LONDON
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
